Trial · NCT00680992
Adverse events239
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 239
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Denosumab 120 mg Q4W (All Cohorts) | 30 | 526 | |
| other | Abdominal pain | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 49 | 526 | |
| other | Constipation | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 60 | 526 | |
| other | Dental caries | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 32 | 526 | |
| other | Diarrhoea | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 60 | 526 | |
| other | Nausea | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 122 | 526 | |
| other | Toothache | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 68 | 526 | |
| other | Vomiting | Gastrointestinal disorders | Denosumab 120 mg Q4W (All Cohorts) | 66 | 526 | |
| other | Asthenia | General disorders | Denosumab 120 mg Q4W (All Cohorts) | 48 | 526 | |
| other | Fatigue | General disorders | Denosumab 120 mg Q4W (All Cohorts) | 142 | 526 | |
| other | Influenza like illness | General disorders | Denosumab 120 mg Q4W (All Cohorts) | 27 | 526 | |
| other | Oedema peripheral | General disorders | Denosumab 120 mg Q4W (All Cohorts) | 46 | 526 | |
| other | Pyrexia | General disorders | Denosumab 120 mg Q4W (All Cohorts) | 47 | 526 | |
| other | Bronchitis | Infections and infestations | Denosumab 120 mg Q4W (All Cohorts) | 28 | 526 | |
| other | Influenza | Infections and infestations | Denosumab 120 mg Q4W (All Cohorts) | 44 | 526 | |
| other | Nasopharyngitis | Infections and infestations | Denosumab 120 mg Q4W (All Cohorts) | 76 | 526 | |
| other | Upper respiratory tract infection | Infections and infestations | Denosumab 120 mg Q4W (All Cohorts) | 48 | 526 | |
| other | Procedural pain | Injury, poisoning and procedural complications | Denosumab 120 mg Q4W (All Cohorts) | 39 | 526 | |
| other | Weight increased | Investigations | Denosumab 120 mg Q4W (All Cohorts) | 30 | 526 | |
| other | Hypercalcaemia | Metabolism and nutrition disorders | Denosumab 120 mg Q4W (All Cohorts) | 29 | 526 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00680992/events